Vaccine News and Research

Latest Vaccine News and Research

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with U.S. Senator Kay Hagan (D-NC) and U.S. Congressman David Price (D-NC), are holding an official groundbreaking ceremony this morning for its U.S. plant-based commercial grade vaccine facility in Research Triangle Park, North Carolina.

1 Oct 2010

Healthy respect for flu this season

Flu season officially begins Friday, Oct. 1, and unlike last year's season when shortages lead to rationing, there will be plenty of vaccine on hand for everyone who wants a flu shot.

1 Oct 2010

FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program

Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.

1 Oct 2010

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.

1 Oct 2010

Antiretroviral therapy does not reduce risk of HIV transmission

For married couples in which one partner is HIV-positive and the other is HIV-negative, antiretroviral therapy (ART) does not reduce the risk of transmitting HIV to the uninfected partner, according to a study from China in the October issue of JAIDS: Journal of Acquired Immune Deficiency Syndromes.

1 Oct 2010

HIV/AIDS researchers, government officials track progress, forecast challenges for HIV vaccine development

More than 1,000 researchers, government officials and advocates are gathering in Atlanta this week to discuss the progress and future challenges in the development of a vaccine that protects against HIV, FierceVaccines reports (Carroll, 9/29). The AIDS Vaccine 2010 meeting, which kicked off Tuesday, will run through Friday, according to the website for the meeting (undated).

1 Oct 2010

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

The National Institute of General Medical Sciences (NIGMS) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $30 million grant to study the structure and function of thousands of biomedically important proteins.

1 Oct 2010

Experts provide information on H1N1 and seasonal flu at Johns Hopkins hospital

Johns Hopkins has a wide range of experts available for interviews and comments about seasonal flu, H1N1, emergency preparedness, infection control, flu transmission in children, vaccine safety, flu treatment, public health ethics, flu in cancer patients, and related public communications strategies. If you would like to interview a Johns Hopkins expert, call or e-mail the designated information officer in the list below.

1 Oct 2010

Prix Galien USA committee honors life saving innovations

The Prix Galien USA committee honored innovations that are saving lives last night during the Prix Galien Awards Gala. The Pro Bono Humanum Award, the Prix Galien USA 2010 and the Prix Galien International were presented and related accomplishments celebrated.

30 Sep 2010

First responders may not be willing to report for work if disaster is a potentially lethal pandemic

Although first responders willingly put themselves in harm's way during disasters, new research indicates that they may not be as willing- if the disaster is a potentially lethal pandemic.

30 Sep 2010

Discovery suggest a new direction for designing vaccines for rare HIV infection

New discoveries about the immune defenses of rare HIV patients who produce antibodies that prevent infection suggest a novel direction for designing new vaccines. Researchers at Rockefeller University and colleagues have now made two fundamental discoveries about the so called broadly neutralizing anti-HIV antibodies, which effectively keep the virus at bay.

30 Sep 2010

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 million from the National Institutes of Health (NIH) Director's Office to further fund Inovio's universal SynCon™ flu vaccine development.

30 Sep 2010

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

Malaria experts focus on RTS, S as Malaria Vaccines for the World Conference begins

Scientists and physicians from around the world gathered in Washington, D.C. on Tuesday for the start of the second Malaria Vaccines for the World Conference, SAPA/News24 reports.

30 Sep 2010

UC Berkeley Extension offers new options for career development in biotechnology

Biotechnology professionals in the Bay Area have three new options for career development from UC Berkeley Extension. The professional programs in Regulatory Affairs, Biopharmaceutical Product and Process Development, and Bioscience Manufacturing and Supply Chain join the education leader's lineup of programs and certificates designed to meet the biotechnology industry's demand for trained professionals.

30 Sep 2010

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent), Merck's vaccine for rotavirus gastroenteritis in infants and children, received the Prix Galien USA 2010 Award for Best Biotechnology Product, Merck announced today.

30 Sep 2010

Precautionary guidelines on flu vaccine safety for allergic children

With the flu season looming and health officials calling for across-the-board immunization, some parents may wonder just how safe the egg-based flu vaccine is for children with allergies. Pretty safe, say pediatricians from Johns Hopkins Children's Center: Even though the flu vaccine contains egg protein, most children with egg and other food allergies can be immunized safely with a few basic precautions.

30 Sep 2010

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

Swine flu no longer a threat to Americans: Report

According to the latest research most Americans are immune to the swine flu virus. Results of the study by the National Institute of Allergy and Infectious Diseases, published in the journal mBio show that around 59 percent of the 310 million U.S. population has developed immunity to H1N1 either from exposure to similar viruses, vaccination, or natural H1N1 infection.

29 Sep 2010

Malaria vaccine close to reality

A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.

29 Sep 2010

Vaccine News and Research

Latest Vaccine News and Research

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Healthy respect for flu this season

FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

Antiretroviral therapy does not reduce risk of HIV transmission

HIV/AIDS researchers, government officials track progress, forecast challenges for HIV vaccine development

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

Experts provide information on H1N1 and seasonal flu at Johns Hopkins hospital

Prix Galien USA committee honors life saving innovations

First responders may not be willing to report for work if disaster is a potentially lethal pandemic

Discovery suggest a new direction for designing vaccines for rare HIV infection

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Circassia announces advancement in T-cell allergy vaccines development

Malaria experts focus on RTS, S as Malaria Vaccines for the World Conference begins

UC Berkeley Extension offers new options for career development in biotechnology

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

Precautionary guidelines on flu vaccine safety for allergic children

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Swine flu no longer a threat to Americans: Report

Malaria vaccine close to reality

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Vaccine News and Research

Latest Vaccine News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in